159857-80-4

• 常用中文名：MC-Val-Cit-PAB
• 常用英文名：MC-Val-Cit-PAB-OH
• CAS号：159857-80-4
• 分子式：C₂₈H₄₀N₆O₇
• 分子量：572.65300
• 相关类别： 信号通路 抗体- 药物偶联物 ADC连接器
• 发布时间：2016-08-10 05:13:08
• 更新时间：2026-07-01 12:02:23
• MC-Val-Cit-PAB是可被组织蛋白酶切割的ADC连接桥，用于制备抗体-药物偶联物。 美国FDA批准的药物，如布伦替卡韦，血清素使用了该连接桥。

名称

• 中文名: N-[6-(2,5-二氢-2,5-二氧代-1H-吡咯-1-基)-1-氧代己基]-L-缬氨酰-N5-(氨基甲酰基)-N-[4-(羟甲基)苯基]-L-鸟氨酰胺
• 英文名: N-[6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N5-carbamoyl-N2-[4-(hydroxymethyl)phenyl]-L-ornithinamide
• 中文别名: 抗体-药物偶联物多肽MC-Val-Cit-PAB; MC-VAL-CIT-PAB-羟基; 6-(2,5-二氧代-2,5-二氢-1-吡咯基)-N-[(S)-1-[[(S)-1-[[4-(羟甲基)苯基]氨基]-1-氧代-5-脲基-2-戊基]氨基]-3-甲基-1-氧代-2-丁基]己酰胺; N-[6-(2,5-二氢-2,5-二氧代-1H-吡咯-1-基)-1-氧代己基]-L-戊酰基-N5-(氨基羰基)-N-[4-(羟甲基)苯基]-L-鸟氨酸酰胺; N- [6-(2,5-二氢-2,5-二氧代-1H-吡咯-1-基)-1-氧代己基] -L-缬氨酰-N; N-[6-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)己酰基]-L-缬氨酰-N5-(氨基甲酰基)-[4-(羟基甲基)苯基]-L-鸟氨酰胺; MC-VAL-CIT-PAB中间体
• 英文别名: N-[6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N5-cbamoyl-N-[4-(hydroxymethyl)phenyl]-L-ornithinamide; Ptide Linkers（ADC Linkers）：MC-Val-Cit-PAB-OH; L-OrnithinaMide, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aMinocbonyl)-N-[4-(hydroxyMethyl)phenyl]; MC-Val-it-PAB; N-[6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N5-cbamoyl-N2-[4-(hydroxymethyl)phenyl]-L-ornithinamide; 6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-[(S)-1-[[(S)-1-[[4-(hydroxymethyl)phenyl]amino]-1-oxo-5-ureidopentan-2-yl]amino]-3-methyl-1-ox; Benzenemethanol,2-chloro-8-nitro; MC-Val-Cit-PAB (ADC ptide linker); N-[6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocbonyl)-N-[4-(hydroxymethyl)phenyl]-L-ornithinamide; ML-Val-Cit-PAB; MC-V-Cit-PAB; 6-(2,5-dioxopyrrol-1-yl)-N-[(1S)-1-[[(1S)-1-[[4-(hydroxymethyl)phenyl]cbamoyl]-4-ureido-butyl]cbamoyl]-2-methyl-propyl]hexanamide; EOS-60616; MC-Val-Cit-PAB; N-[6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocbonyl)-N-[4-(hydroxymeth; MC-Val-Cit-PAB, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocbonyl)-N-[4-(hydroxymethyl)phenyl]; 6-(2,5-Dioxo-2,5-dihydro-1-pyrrolyl)-N-[(S)-1-[[(S)-1-[[4-(hydroxymethyl)phenyl]amino]-1-oxo-5-ureido-2-pentyl]amino]-3-methyl-1-oxo-2-butyl]hexanamide; MC-Val-Cit-PAB/MC-VC-PAB-OH; 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)hexanamide; N-[(2S)-1-[[(2S)-5-(cbamoylamino)-1-[4-(hydroxymethyl)anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-6-(2,5-dioxopyrrol-1-yl)hexanamide

物化性质

• 密度: 1.276
• 分子式: C₂₈H₄₀N₆O₇
• 分子量: 572.65300
• 精确质量: 572.29600
• PSA: 210.70000
• LogP: 3.27310
• 储存条件: 2-8℃

生物活性

• 描述: MC-Val-Cit-PAB是可被组织蛋白酶切割的ADC连接桥,用于制备抗体-药物偶联物。 美国FDA批准的药物,如brentuximab vedotin使用了该连接桥。
• 相关类别:
  信号通路 >> 抗体- 药物偶联物 >> ADC连接器
  研究领域 >> 癌症
• 靶点:

  ADC linker[1]

• 参考文献:

  [1]. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders

合成路线

55750-63-5 159857-79-1 ~94% 159857-80-4

文献：SEATTLE GENETICS, INC. Patent: WO2007/8848 A2, 2007 ; Location in patent: Page/Page column 108; 136; 137 ;